AN41-- NCPTSD DHMC CPSR Coreview on SAM.gov

This is not a solicitation. The Department of Veterans Affairs intends to negotiate a requirement with Mary Hitchcock Memorial Hospital, 1 Medical Center Dr, NH 03756. The applicable NAICS code is 541715 and PSC is AN41. The authority for this action is FAR 13.106-1(b)(2): Only one Responsible Source and No Other Supplies or Services Will Satisfy Agency Requirements. Interested persons may contact the Contracting Specialist via email at ophelia.wilson@va.gov regarding this procurement. The determination to conduct a competitive procurement based on responses to this notice is solely within the discretion of the Contracting Officer. Item description: Clinical pharmacology services for research. This contract is to create a blanket purchasing agreement to fully utilize the Clinical Pharmacology Shared Resource (CPSR) core at Dartmouth, the academic affiliate of the White River Junction VA Healthcare System. Creating this agreement will facilitate the utilization of an established core to perform services for funded investigators, which will improve output for existing research laboratories and further improve research productivity at the White River Junction VA. This agreement will allow investigators to purchase services as needed throughout the year. It is not feasible to use a purchase card to pay for services for each individual project, due to VA restrictions on service limits. Implementing a larger purchasing range with this agreement will support the capacity of current and anticipated work. This option will also eliminate the need to create multiple contracts utilizing the same services, thus eliminating redundancies, unnecessary paperwork, and excessive use of staff time. This mechanism will save time, improve productivity, and reduce unnecessary government spending. Pharmacokinetic and pharmacodynamic methodology and analysis of study samples will be performed on de-identified pre-clinical and clinical samples. Expected purchases may include: Biospecimen processing storage and distribution. Bioanalytical analyses, including method development, validation, and implementation of LC­MS/MS and LC-UV based analytical methods for quantitative determination of drugs, drug metabolites, and endogenous metabolites in biosamples. Pharmacokinetic (PK) and/or pharmacodynamic (PD) studies in clinical and pre-clinical studies, including consultation, method development, and experimental design. PK and PK-PD data analysis and modeling: providing state of the art compartmental and non-compartmental PK analysis, direct and indirect modeling of PD data, and evaluation of dose-exposure-response relationships to provide data-guided optimization of drug dosing regimens. In vitro pharmacology: providing drug-drug combination-effect (e.g., cytotoxicity) data generation and analysis based on the Chou-Talalay median-effect model using CalcuSyn software. Salient characteristics: Dedicated, highly trained staff with scientific oversight. Expertise in pharmacokineti…